| セッション情報 |
パネルディスカッション8(肝臓学会・消化器病学会合同)
東アジアにおける肝疾患の問題点と治療の特色
|
| タイトル |
肝PD8-8指：Prevention of the emerging hepatitis in Asia: HEV
|
| 演者 |
J. W. K. Shih（National Institute of Diagnostics and Vaccine Development, School of Public Health, Xiamen University） |
| 共同演者 |
J. Zhang（National Institute of Diagnostics and Vaccine Development, School of Public Health, Xiamen University） |
| 抄録 |
The hepatitis E vaccine, HEV239 (Hecolin), is commercially available in China since 2012. The vaccine has been shown in a large Phase III clinical trial to be well tolerated by adults and confer 100% protection against hepatitis E caused by both genotypes 1 and 4. Protective immunity was found to develop after 2 vaccine doses given one month apart. The data showed that the vaccine affords 80% protection against HEV infection and suggests that the vaccine is safe for pregnant women. This protection has been monitored for more than 3 years and reminds to be effective. These findings show that HEV239 vaccine cross protects against infection and disease caused by HEV genotypes 1 and 4 and could be used to prevent and interrupt outbreaks of waterborne infection caused by genotype 1, and possibly genotype 2 virus, in developing countries and to protect travelers to these countries. Although uncommon, HEV has emerged to be the principle cause of viral hepatitis and the most severe form of acute hepatitis in many developed countries. The vaccine might be beneficial for the elderly populations in some of these countries, who are at high risk of infection. Further clinical trials are being initiated to determine efficacy of the vaccine against genotypes 2 and 3 and for high risk groups, such as pregnant women, subjects with chronic liver diseases and organ transplant recipients. |
| 索引用語 |
HEV, Vaccine |
